Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1984 1
1989 1
1990 1
1991 4
1992 2
1993 2
1994 1
1995 1
1996 2
1999 1
2000 4
2001 1
2002 5
2003 5
2004 3
2006 4
2007 2
2008 2
2009 6
2010 3
2011 6
2012 6
2013 7
2014 4
2015 5
2016 11
2017 9
2018 4
2019 15
2020 7
2021 15
2022 8
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma"
Page 1
European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders.
Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. Al-Toma A, et al. United European Gastroenterol J. 2019 Jun;7(5):583-613. doi: 10.1177/2050640619844125. Epub 2019 Apr 13. United European Gastroenterol J. 2019. PMID: 31210940 Free PMC article.
In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline also deals with other gluten-related disorders, such as dermatitis herpetiformis, which is a cutaneous manifestation of CD characteri …
In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline …
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Sibaud V, et al. Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. Am J Clin Dermatol. 2020. PMID: 32613545 Review.
It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR), SRC, and other kinases of the TEC family (interleukin-2-inducible T-cell kinase [ITK], Tec, BMX). Dermatological toxicities …
It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR …
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L. Shustov A, et al. Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. Cancer Treat Res. 2019. PMID: 30596216 Review.
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes t …
Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature …
Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H, Miyagaki T. Kamijo H, et al. Curr Treat Options Oncol. 2021 Jan 7;22(2):10. doi: 10.1007/s11864-020-00809-w. Curr Treat Options Oncol. 2021. PMID: 33415447 Review.
For advanced-stage MF/SS, systemic treatments by biological or targeted therapies including bexarotene and interferon either alone or in combination are tried first, with more immunosuppressive chemotherapies being reserved for refractory or rapidly progressive disease. Re …
For advanced-stage MF/SS, systemic treatments by biological or targeted therapies including bexarotene and interferon either alone or in com …
Transplantation.
Zain J. Zain J. Cancer Treat Res. 2019;176:269-287. doi: 10.1007/978-3-319-99716-2_13. Cancer Treat Res. 2019. PMID: 30596223
Mature T-cell non-Hodgkin lymphomas (T-cell NHL) are a heterogeneous group of lymphoid malignancies including NK/T-cell lymphomas. ...Allogeneic stem cell transplantation harnesses the graft-versus-lymphoma effect, providing long-t …
Mature T-cell non-Hodgkin lymphomas (T-cell NHL) are a heterogeneous group of lymphoid malignancies including NK …
Disorders of Hypopigmentation.
Dina Y, McKesey J, Pandya AG. Dina Y, et al. J Drugs Dermatol. 2019 Mar 1;18(3):s115-s116. J Drugs Dermatol. 2019. PMID: 30909355
Treatment options currently include psychological counseling, topical therapy, systemic therapy, phototherapy, surgical therapy, and depigmentation. In patients with stable, refractory disease, successful repigmentation has been achieved using mini-punch grafting, blister …
Treatment options currently include psychological counseling, topical therapy, systemic therapy, phototherapy, surgical therapy, and depigme …
Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V, Zhou Y. Van-de-Velde V, et al. J Cutan Med Surg. 2019 May/Jun;23(3):319-327. doi: 10.1177/1203475419840629. Epub 2019 Apr 3. J Cutan Med Surg. 2019. PMID: 30943788 Review.
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. ...Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, received extended approval …
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration o …
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P, Wang Y. Lai P, et al. Cancer Biol Med. 2021 Feb 15;18(1):34-51. doi: 10.20892/j.issn.2095-3941.2020.0216. Cancer Biol Med. 2021. PMID: 33628583 Free PMC article. Review.
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. ...These epigenetic regulators are essential in the development of CTCL and provide new insights into the clinical treatments of this refractory disease. …
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. ...These epigenetic …
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M, Kopp E, McCann S, Cantrell W. Tawa M, et al. Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80. Clin J Oncol Nurs. 2019. PMID: 31322628 Review.
BACKGROUND: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sezary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. Mogamulizumab is a first-in-class monoclonal antibody that selectively binds to C-C chem …
BACKGROUND: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sezary syndrome (SS) …
Peripheral T-cell lymphoma in children and adolescents: a single-institution experience.
Al Mahmoud R, Weitzman S, Schechter T, Ngan B, Abdelhaleem M, Alexander S. Al Mahmoud R, et al. J Pediatr Hematol Oncol. 2012 Nov;34(8):611-6. doi: 10.1097/MPH.0b013e3182707592. J Pediatr Hematol Oncol. 2012. PMID: 23042011 Review.
Data were abstracted through a detailed retrospective review of patient charts. Those with isolated cutaneous T-cell lymphoma were excluded from this analysis. RESULTS: Thirteen patients were diagnosed with PTCL during the 10-year period. ...According …
Data were abstracted through a detailed retrospective review of patient charts. Those with isolated cutaneous T-cell …
143 results